QuintilesIMS Institute study funded by the National Organization for Rare Disorders concludes orphan drugs accounted for only 7.9% of US total drug spending in 2016, bolstering advocacy group's view that rare disease treatments are not responsible for rising healthcare costs. US FDA analysis finds most orphan drugs do not expand their labeled indications into non-rare disease settings.
Bolstered by external analyses on drug spending and orphan drug approvals, the National Organization for Rare Disorders (NORD) is trying to make the case against legislative changes to the Orphan Drug Act.
The rare disease advocacy group is highlighting the results of a QuintilesIMS Institute report showing that orphan drugs account for...